258 related articles for article (PubMed ID: 35738312)
1. Recent progress in antibody-based therapeutics for triple-negative breast cancer.
Ning WJ; Liu X; Zeng HY; An ZQ; Luo WX; Xia NS
Expert Opin Drug Deliv; 2022 Jul; 19(7):815-832. PubMed ID: 35738312
[TBL] [Abstract][Full Text] [Related]
2. Bispecific Antibodies for Triple Negative Breast Cancer.
Dees S; Ganesan R; Singh S; Grewal IS
Trends Cancer; 2021 Feb; 7(2):162-173. PubMed ID: 33041246
[TBL] [Abstract][Full Text] [Related]
3. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in targeted strategies for triple-negative breast cancer.
Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic interventions of Triple Negative Breast Cancer.
Li Z; Qiu Y; Lu W; Jiang Y; Wang J
J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
[TBL] [Abstract][Full Text] [Related]
6. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
8. Emerging treatment approaches for triple-negative breast cancer.
Capuozzo M; Celotto V; Santorsola M; Fabozzi A; Landi L; Ferrara F; Borzacchiello A; Granata V; Sabbatino F; Savarese G; Cascella M; Perri F; Ottaiano A
Med Oncol; 2023 Dec; 41(1):5. PubMed ID: 38038783
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer.
Elizabeth MS; Cristina SBJ; Christian CG
Mini Rev Med Chem; 2024; 24(4):431-439. PubMed ID: 37198990
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer.
Al Jarroudi O; El Bairi K; Curigliano G; Afqir S
Cancer Treat Res; 2023; 188():1-27. PubMed ID: 38175340
[TBL] [Abstract][Full Text] [Related]
11. Progress and challenges of immunotherapy in triple-negative breast cancer.
Zhu Y; Zhu X; Tang C; Guan X; Zhang W
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
[TBL] [Abstract][Full Text] [Related]
12. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer.
Dees S; Ganesan R; Singh S; Grewal IS
Mol Cancer Ther; 2020 Dec; 19(12):2409-2421. PubMed ID: 33087511
[TBL] [Abstract][Full Text] [Related]
13. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
Lee A; Djamgoz MBA
Cancer Treat Rev; 2018 Jan; 62():110-122. PubMed ID: 29202431
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer.
Yao HP; Suthe SR; Hudson R; Wang MH
Drug Discov Today; 2020 Jul; 25(7):1160-1173. PubMed ID: 32479905
[TBL] [Abstract][Full Text] [Related]
15. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Weiss J; Glode A; Messersmith WA; Diamond J
Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
[No Abstract] [Full Text] [Related]
16. Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.
Torres ETR; Emens LA
Breast Cancer Res Treat; 2022 Jan; 191(2):291-302. PubMed ID: 34716871
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
Zardavas D
Expert Opin Investig Drugs; 2022 Jun; 31(6):633-644. PubMed ID: 35451891
[TBL] [Abstract][Full Text] [Related]
18. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape.
Uliano J; Nicolò E; Corvaja C; Taurelli Salimbeni B; Trapani D; Curigliano G
Expert Rev Clin Pharmacol; 2022 Dec; 15(12):1399-1413. PubMed ID: 36317756
[TBL] [Abstract][Full Text] [Related]
19. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab and atezolizumab in triple-negative breast cancer.
Kwapisz D
Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]